Tony Navas

3.6k total citations · 1 hit paper
32 papers, 2.6k citations indexed

About

Tony Navas is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Tony Navas has authored 32 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Tony Navas's work include Multiple Myeloma Research and Treatments (5 papers), Melanoma and MAPK Pathways (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Tony Navas is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Melanoma and MAPK Pathways (5 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Tony Navas collaborates with scholars based in United States, South Korea and Japan. Tony Navas's co-authors include Paul J. Godowski, Stephen J. Elledge, Sean Lyons, James Madara, Andrew T. Gewirtz, Zheng Zhou, Daryl T. Baldwin, Timothy A. Stewart, James B. Allen and Yolanda Sánchez and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Tony Navas

31 papers receiving 2.6k citations

Hit Papers

Cutting Edge: Bacterial Flagellin Activates Basolaterally... 2001 2026 2009 2017 2001 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cutting Edge: Bacterial Flagellin Activates Basolaterally Expressed TLR5 to Induce Epithelial Proinflammatory Gene Expression
    2001 1.1k citations Andrew T. Gewirtz, Tony Navas et al. The Journal of Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tony Navas United States 14 1.4k 1.1k 328 320 216 32 2.6k
Atsushi Hase Japan 18 1.7k 1.2× 1.2k 1.1× 415 1.3× 311 1.0× 109 0.5× 55 3.3k
Nesrin Özören Türkiye 19 2.7k 1.9× 1.8k 1.7× 294 0.9× 266 0.8× 111 0.5× 29 3.6k
Yi‐Nan Gong United States 16 2.6k 1.8× 1.5k 1.4× 185 0.6× 179 0.6× 107 0.5× 26 3.5k
Agnes Fütterer Spain 18 1.0k 0.7× 1.4k 1.3× 376 1.1× 300 0.9× 106 0.5× 24 2.6k
Kevin W. Bruhn United States 24 938 0.7× 1.5k 1.4× 605 1.8× 246 0.8× 58 0.3× 36 2.7k
Jin Gohda Japan 24 1.2k 0.8× 966 0.9× 388 1.2× 673 2.1× 81 0.4× 48 2.4k
Thomas Powell United States 16 1.1k 0.7× 753 0.7× 362 1.1× 300 0.9× 112 0.5× 31 2.4k
Lianfa Shi Canada 15 2.3k 1.6× 1.1k 1.1× 584 1.8× 275 0.9× 157 0.7× 18 3.6k
Atsushi Kumatori Japan 28 1.4k 1.0× 979 0.9× 559 1.7× 193 0.6× 126 0.6× 44 2.8k
María José Martínez‐Lorenzo Spain 25 1.1k 0.8× 742 0.7× 185 0.6× 289 0.9× 69 0.3× 31 2.1k

Countries citing papers authored by Tony Navas

Since Specialization
Citations

This map shows the geographic impact of Tony Navas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tony Navas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tony Navas more than expected).

Fields of papers citing papers by Tony Navas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tony Navas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tony Navas. The network helps show where Tony Navas may publish in the future.

Co-authorship network of co-authors of Tony Navas

This figure shows the co-authorship network connecting the top 25 collaborators of Tony Navas. A scholar is included among the top collaborators of Tony Navas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tony Navas. Tony Navas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mittra, Arjun, Geraldine O’Sullivan Coyne, Jennifer Zlott, et al.. (2023). Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. Cancer Chemotherapy and Pharmacology. 93(3). 177–189. 2 indexed citations
3.
Kummar, Shivaani, Apurva K. Srivastava, Tony Navas, et al.. (2021). Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Investigational New Drugs. 39(6). 1577–1586. 6 indexed citations
4.
Navas, Tony, Thomas D. Pfister, Simona Colantonio, et al.. (2018). Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells. PLoS ONE. 13(6). e0199361–e0199361. 9 indexed citations
5.
Srivastava, Apurva K., Tony Navas, Melinda G. Hollingshead, et al.. (2017). Effective implementation of novel MET pharmacodynamic assays in translational studies. Annals of Translational Medicine. 5(1). 3–3. 8 indexed citations
6.
Meehan, Robert, Alice P. Chen, Geraldine O’Sullivan Coyne, et al.. (2017). Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations. Cancer Research. 77(13_Supplement). 4678–4678. 1 indexed citations
7.
Srivastava, Apurva K., Melinda G. Hollingshead, Jennifer Weiner, et al.. (2016). Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. Clinical Cancer Research. 22(14). 3683–3694. 24 indexed citations
8.
Navas, Tony, Thomas D. Pfister, Scott M. Lawrence, et al.. (2015). Abstract 5082: Impact of HGF knockin microenvironment on epithelial-mesenchymal transition and cancer stem cells in a non-small cell lung cancer xenograft model. Cancer Research. 75(15_Supplement). 5082–5082. 1 indexed citations
9.
Balasubramanian, Priya, Lihua Wang, Scott M. Lawrence, et al.. (2014). Abstract 3062: Isolation and characterization of circulating tumor cells (CTCs) from peripheral blood specimens of patients with advanced solid tumor malignancies (using ApoStream™ instrumentation). Cancer Research. 74(19_Supplement). 3062–3062. 1 indexed citations
10.
Navas, Tony, Li Zhou, Myka L. Estes, et al.. (2008). Inhibition of p38α MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leukemia & lymphoma. 49(10). 1963–1975. 28 indexed citations
11.
Medicherla, Satyanarayana, Andrew A. Protter, Ying Jing, et al.. (2006). Preventive and Therapeutic Potential of p38α-Selective Mitogen-Activated Protein Kinase Inhibitor in Nonobese Diabetic Mice with Type 1 Diabetes. Journal of Pharmacology and Experimental Therapeutics. 318(1). 99–107. 13 indexed citations
12.
Nguyen, Aaron, Elizabeth G. Stebbins, Margaret Henson, et al.. (2006). Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Experimental Cell Research. 312(10). 1909–1923. 49 indexed citations
13.
Schmidt, Kerstin, Mandy Kwong, Kol A. Zarember, et al.. (2004). APC-Independent Activation of NK Cells by the Toll-Like Receptor 3 Agonist Double-Stranded RNA. The Journal of Immunology. 172(1). 138–143. 195 indexed citations
14.
Hideshima, Teru, Klaus Podar, Dharminder Chauhan, et al.. (2004). p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 23(54). 8766–8776. 105 indexed citations
15.
Hideshima, Teru, Klaus Podar, Dharminder Chauhan, et al.. (2004). P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.. Blood. 104(11). 3348–3348. 5 indexed citations
16.
Gewirtz, Andrew T., Tony Navas, Sean Lyons, Paul J. Godowski, & James Madara. (2001). Cutting Edge: Bacterial Flagellin Activates Basolaterally Expressed TLR5 to Induce Epithelial Proinflammatory Gene Expression. The Journal of Immunology. 167(4). 1882–1885. 1053 indexed citations breakdown →
17.
Navas, Tony, Daryl T. Baldwin, & Timothy A. Stewart. (1999). RIP2 Is a Raf1-activated Mitogen-activated Protein Kinase Kinase. Journal of Biological Chemistry. 274(47). 33684–33690. 81 indexed citations
18.
Sun, Xiaoqing, James Lee, Tony Navas, et al.. (1999). RIP3, a Novel Apoptosis-inducing Kinase. Journal of Biological Chemistry. 274(24). 16871–16875. 197 indexed citations
19.
Navas, Tony, Zheng Zhou, & Stephen J. Elledge. (1995). DNA polymerase ϵ links the DNA replication machinery to the S phase checkpoint. Cell. 80(1). 29–39. 363 indexed citations
20.
Elledge, Stephen J., Zheng Zhou, James B. Allen, & Tony Navas. (1993). DNA damage and cell cycle regulation of ribonucleotide reductase. BioEssays. 15(5). 333–339. 201 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atsushi Hase Breakdown of academic impact, for papers by Nesrin Özören Breakdown of academic impact, for papers by Yi‐Nan Gong Breakdown of academic impact, for papers by Agnes Fütterer Breakdown of academic impact, for papers by Kevin W. Bruhn Breakdown of academic impact, for papers by Jin Gohda Breakdown of academic impact, for papers by Thomas Powell Breakdown of academic impact, for papers by Lianfa Shi Breakdown of academic impact, for papers by Atsushi Kumatori Breakdown of academic impact, for papers by María José Martínez‐Lorenzo
Rankless by CCL
2026